Home  >  Press Releases  >  Financial
Share

Press Releases

Press release year list 2020 2019 2018 2017 2016 2015 2014 2013 2012
August 6, 2020
Reports Flat Revenue of $1.5 Billion, and Net Income of $377 Million, or $0.79 per Diluted Share, Increasing 2% and 3%, Respectively, on a Reported Basis for Second Quarter 2020 Reports Adjusted Net Income of $427 Million, or Adjusted Diluted EPS of $0.89 for Second Quarter 2020 Delivers 4% Operational Growth in Revenue and 4% Operational Growth in Adjusted Net Income for Second Quarter 2020 Raises and Narrows Full Year 2020 Revenue Guidance to $6.300 - $6.475 Billion and Diluted EPS of $3.14 - $3.32 on a Reported Basis, or $3.52 - $3.68 on an Adjusted Basis Zoetis Inc . (NYSE: ZTS) today reported its financial results for the second quarter of 2020 and raised and narrowed its guidance for full year 2020 to reflect the company’s current view of the estimated full-year impact of the COVID-19 pandemic and foreign currency headwinds. The company reported revenue of $1.5 billion for the second quarter of 2020, which is flat compared with the second quarter of 2019. Net income for the ...
June 26, 2020
Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Aug. 6, 2020. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Glenn David will review second quarter 2020 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations . Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on Aug. 6, 2020. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. ...
June 8, 2020
Zoetis Inc. (NYSE:ZTS) will participate in the William Blair 40th Annual Growth Stock Conference on Thursday, June 11, 2020. Glenn David, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 12:20 p.m. ET (11:20 a.m. CT). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations . A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, ...
May 20, 2020
Zoetis Inc . (NYSE:ZTS) today announced the results of shareholder voting at its 2020 Annual Meeting of Shareholders and provided details on its third quarter 2020 dividend. Virtual Annual Meeting of Shareholders Zoetis held a virtual annual meeting today, with Chairman Michael B. McCallister presiding over the business portion of the meeting and shareholder voting. Chief Executive Officer Kristin Peck discussed the company’s strong performance in 2019, the essential role that Zoetis plays in sustaining and protecting animal and human life during the COVID-19 pandemic, and its top priorities for continued growth and market leadership in the global animal health industry. As part of her remarks about the company, Peck said, “In 2019, we achieved operational revenue growth of 10% and grew adjusted net income 14% operationally, while continuing to create value for our investors.” “As we started 2020, none of us could have predicted the circumstances we would face as a company and a ...
May 18, 2020
Zoetis Inc. (NYSE:ZTS) will participate in the Stifel 2020 Virtual Jaws & Paws Conference on Wednesday, May 27, 2020. Kristin Peck, Chief Executive Officer, will represent the company and respond to questions from analysts. She is scheduled to present at 12:40 p.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations . A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who raise and care for ...
May 7, 2020
Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.25 billion of senior notes, consisting of $750 million aggregate principal amount of 2.000% senior notes due 2030 and $500 million aggregate principal amount of 3.000% senior notes due 2050, in an underwritten public offering. Zoetis intends to use the net proceeds to repay the principal of our 3.450% senior notes due 2020 in the aggregate principal amount of $500 million and for general corporate purposes. The offering is expected to close on May 12, 2020, subject to customary closing conditions. Barclays Capital Inc., BofA Securities, Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC and MUFG Securities Americas Inc. are acting as joint book-running managers of the underwriters. The final prospectus supplement and accompanying prospectus, when available, may be accessed through the SEC’s website at www.sec.gov . Alternatively, the issuer, the underwriters or any dealer participating in the offering ...
May 6, 2020
Reports Revenue of $1.5 Billion, Growing 5%, and Net Income of $423 Million, or $0.88 per Diluted Share, Increasing 36% and 35%, Respectively, on a Reported Basis for First Quarter 2020 Reports Adjusted Net Income of $455 Million, or Adjusted Diluted EPS of $0.95, for First Quarter 2020 Delivers 7% Operational Growth in Revenue and 10% Operational Growth in Adjusted Net Income for First Quarter 2020 COVID-19 Pandemic Has Minimal Impact on First Quarter Results; Estimated Full-Year Impact Reflected in Lower 2020 Guidance Updates Full Year 2020 Revenue Guidance to $5.950 - $6.250 Billion and Diluted EPS of $2.80 - $3.07 on a Reported Basis, or $3.17 - $3.42 on an Adjusted Basis Zoetis Inc. (NYSE: ZTS) today reported its financial results for the first quarter of 2020 and lowered its guidance for full year 2020 to reflect the company’s current view of the estimated full-year impact of the COVID-19 outbreak, recessionary conditions in the global economy, and foreign currency headwinds. ...
April 30, 2020
Launched by leading animal health company Zoetis Uniquely combines preventive care with best-in-class health insurance for dogs and cats Pumpkin Insurance Services , Inc. (“Pumpkin”), a new pet insurance agency and pet care company, announced today the launch of its new insurance and optional monthly preventive care plans for pet owners in the U.S. Launched by Zoetis (NYSE:ZTS), the world’s largest global animal health company, Pumpkin is now available to consumers in many states. 1 With its holistically designed plans, Pumpkin addresses a gap in the pet care industry by offering competitive pet health insurance and preventive care so pet owners can help their pets stay healthy year-round. Rather than wait until animals are sick or injured to provide care, Pumpkin’s Preventive Essentials plan – available at an additional cost to the core insurance plan – helps enable families to give their pets crucial routine care that veterinarians universally recommend for cats and dogs. ...
April 17, 2020
Zoetis Inc. (NYSE: ZTS) has been notified of an unsolicited “mini-tender offer” by TRC Capital Investment Corporation (“TRC”) to purchase up to 1,000,000 shares of Zoetis common stock, representing approximately 0.21% of the outstanding shares of Zoetis common stock. TRC’s offer price of $109.00 per share is approximately 4.9% lower than the $114.61 closing price per share of Zoetis common stock on April 3, 2020, the last trading day before the commencement of the offer, and approximately 14.5% below the $127.45 closing price per share of Zoetis common stock on April 16, 2020, the last trading day before the date of this press release. TRC has made similar, unsolicited mini-tender offers for shares of other publicly traded companies. Zoetis does not endorse TRC’s unsolicited mini-tender offer and is not associated in any way with TRC, its mini-tender offer or its mini-tender offer documents. TRC’s offer price is below the current market value for shares of Zoetis common stock. In ...
April 1, 2020
Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Wednesday, May 6, 2020. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Glenn David will review first quarter 2020 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations . Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on May 6, 2020. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis ...
February 27, 2020
Simparica Trio marks the first all-in-one protection in the U.S. against heartworm disease, ticks* and fleas, roundworms and hookworms** in a single monthly chewable First parasiticide to combine sarolaner, moxidectin and pyrantel First combination isoxazoline for dogs in the U.S. New product protects against many of the most common parasites and gives veterinarians and pet owners a convenient option for comprehensive protection Zoetis today announced that the U.S. Food and Drug Administration (FDA) has approved Simparica Trio TM (sarolaner, moxidectin, and pyrantel chewable tablets), the first once-monthly, chewable tablet in the U.S. that delivers all-in-one protection from heartworm disease, ticks and fleas, roundworms and hookworms. This combination product builds on the trusted legacy of Simparica ® (sarolaner) Chewables and exemplifies Zoetis’ dedication to innovation in parasiticides. “Today’s approval of Simparica Trio in the United States provides veterinarians with a new and ...
February 21, 2020
Zoetis Inc. (NYSE:ZTS) will participate in the Cowen and Company 40th Annual Health Care Conference on Monday, March 2, 2020, in Boston, Mass. Kristin Peck, Chief Executive Officer, will represent the company and respond to questions from analysts. She is scheduled to present at 2:10 p.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who ...
February 13, 2020
For Fourth Quarter 2019, Zoetis Reports Revenue of $1.7 Billion, Growing 7%, and Net Income of $384 Million, or $0.80 per Diluted Share, on a Reported Basis Reports Adjusted Net Income of $440 Million, or Adjusted Diluted EPS of $0.92, for Fourth Quarter 2019 Delivers 9% Operational Growth in Revenue and 13% Operational Growth in Adjusted Net Income for Fourth Quarter 2019 For Full Year 2019, Zoetis Reports Revenue of $6.3 Billion, Growing 7%, and Net Income of $1.5 Billion, or $3.11 per Diluted Share, on a Reported Basis Reports Adjusted Net Income of $1.8 Billion, or Adjusted Diluted EPS of $3.64, for Full Year 2019 Delivers 10% Operational Growth in Revenue and 14% Operational Growth in Adjusted Net Income for Full Year 2019 Provides Full Year 2020 Revenue Guidance of $6.650 - $6.800 Billion, with Diluted EPS of $3.53 - $3.65 on a Reported Basis, or $3.90 - $4.00 on an Adjusted Basis Zoetis Inc. (NYSE: ZTS) today reported its financial results for the fourth quarter and full year ...
February 11, 2020
The Board of Directors of Zoetis Inc . (NYSE:ZTS) has declared a second quarter 2020 dividend payable to holders of the company’s common stock of $0.20 per share. The dividend is to be paid on Monday, June 1, 2020, to holders of record on Friday, April 17, 2020. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2018, the company generated annual revenue of $5.8 billion with approximately 10,000 employees. For more information, visit www.zoetis.com . DISCLOSURE NOTICES Forward-Looking Statements: This press ...
February 10, 2020
Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Merrill Lynch Animal Health Summit on Monday, Feb. 24, 2020, in New York, N.Y. Glenn David, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 8:40 a.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and a range of services. Zoetis serves veterinarians, livestock ...
January 2, 2020
Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Feb. 13, 2020. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Glenn David will review fourth quarter and full year 2019 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on Feb. 13, 2020. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and a range of ...